Influence of Simvastatin on Apolipoprotein B-100 (apoB-100) Secretion

Summary

3-Hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) decrease apolipoprotein B-100-containing lipoproteins by increasing their fractional catabolic rates through low-density lipoproteins (LDL) receptor-mediated uptake. Their influence on hepatic secretion of these lipoproteins is controversial. The current study investigates whether simvastatin influences lipoprotein secretion.

Timeline

Start

1998-11

Primary completion

1999-03

Completion

2000-03

Drugs

Indications